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Paralysis Case and 
Contact Spread of 
Recombinant 
Vaccine–derived 
Poliovirus, Spain
To the Editor: The World Health 
Organization Polio Eradication Initia-
tive has reduced to 4 the number of 
countries with endemic transmission 
of wild polioviruses and has reported 
the widespread circulation of poliovi-
ruses that have evolved from attenu-
ated vaccine (oral poliovirus vaccine 
[OPV]), so-called vaccine-derived 
polioviruses (VDPVs) (1,2). VDPVs 
can reportedly replicate in immuno-
compromised persons, in whom they 
produce paralysis, and can spread to 
contacts and produce paralytic polio 
in immunocompetent but incomplete-
ly immunized persons; these viruses 
can even cause some polio outbreaks 
in areas with a low level of vaccina-
tion coverage (2). When VDPVs are 
detected, a careful follow-up of VDPV 
cases and contacts is essential if spread 
is to be avoided. Because point muta-
tions or recombination events have 
been associated with reversion to neu-
rovirulence transmission and thus a 
greater probability of outbreaks (2), 
meticulous molecular studies of the 
detected strains are recommended.
Spain progressively adopted 
vaccination with OPV for children in 
2004. As a consequence, the incidence 
of vaccine-like poliovirus detection in 
recently vaccinated children, which 
was relatively common up to that time 
(51 isolates in 2003) (3), began to de-
crease (15 isolates in 2004 and none 
in 2005 except the case described 
here). In July 2005, a 14-month-old 
boy from Morocco with residual pa-
ralysis and major histocompatibil-
ity class II immunodeﬁ  ciency  was 
reported through the Spanish Acute 
Flaccid Paralysis Surveillance Sys-
tem. The patient had received 2 OPV 
doses at birth and at 6 months of age 
in Morocco; 8 months later, meningo-
encephalitis developed. The case was 
immediately considered suspicious 
and was therefore monitored at least 
monthly until the boy died. Sampling 
was conducted, coinciding with his 
visits to the hospital to receive ther-
apy with immunoglobulin (γ globulin 
0.5 g/kg). His contacts were studied, 
environmental surveillance was con-
ducted, and molecular analysis of 
all detected viruses was performed. 
Laboratory methods for virus detec-
tion and characterization, including 
10 new reverse-transcription–PCRs 
designed to cover the entire genome, 
are detailed in the Table. 
Serotype 2 VDPVs were detected 
in all 10 stool samples of the patient 
with residual paralysis for 6 months, 
until he died, and in 3 of the 7 family 
contacts analyzed (father and 2 broth-
ers, 11 and 13 years of age, none with 
conﬁ  rmed previous vaccination). One 
of the contacts, considered immuno-
competent, shed virus for 216 days (5 
fecal samples in which 5 complete ge-
nomes were obtained and 1 additional 
fecal sample in which virus capsid 
protein l [VP1] could be ampliﬁ  ed); 
a stool sample collected on day 284 
was negative. Technical problems de-
layed sewage sampling. When sewage 
from the area in which the patient and 
positive contacts lived was sampled 
on February 8, 2006, no polioviruses 
were detected; however, an echovirus 
30 was detected. Poliovirus viral load 
ﬂ  uctuated (106–109 copies/mL in the 
paralysis-affected person), decreasing 
after each immunoglobulin therapy 
dose (Figure 1 in online Technical Ap-
pendix, available from www.cdc.gov/
EID/content/14/11/1807-Techapp.
pdf). The corresponding level was 
<105 in the contacts. The highest value 
of viral load was recorded in the pa-
tient’s  ﬁ  nal sample, taken before he 
died. Homology of the VP1 gene with 
respect to the original vaccine PV2 
ﬂ  uctuated from 97.8% to 98.6% in the 
case samples but remained constant 
(98.4%) in the contact samples (Figure 
1 in online Technical Appendix). All 
studied polioviruses featured the fol-
lowing nucleotide substitutions in the 
5′ untranslated region: G309A, T344C, 
T355C, T398C, A481G, T500C, and 
T743C (Figure 2 in online Techni-
cal Appendix). Furthermore, the ﬁ  nal 
sample from the patient had A476C, 
G505T, T588A, and A738C. Several 
nucleotide substitutions detected in 
VP1–4 were common to all samples 
(Figure 2 in online Technical Appen-
dix); 5 resulted in amino acid changes, 
including T2909C (VP1 I143T) and 
G3277A (VP1 V266I). All samples 
contained 2 noncontiguous recombi-
nation fragments Sabin 2/Sabin 1 in 
the nonstructural genes, including the 
entire 3C gene and the 3′ half of the 
3D-pol (Figure 2 in online Technical 
Appendix) as in other reports (7–10). 
Both fragments, when compared with 
C species enterovirus, were closely 
related to Sabin 1 (99.6% and 97.9%, 
respectively). Speciﬁ  c nucleotide and 
amino acid comparisons among the 
isolates are detailed in Figure 3 in the 
online Technical Appendix.
According to the proposed clas-
siﬁ  cation (2), all the detected viruses 
were iVDPVs (isolated from immu-
nocompromised patients) that spread 
only to close contacts because they 
were not detected in local sewage. If 
we assume that the greater the amount 
of viral excretion in feces that occurs, 
the higher number of replicating po-
lioviruses (as well as the potential for 
greater genetic diversity), the patient 
had a more active infection (that re-
sponded to the therapy) than did the 
contacts. Fluctuation in homology to 
the parental OPV strain might be due 
not only to the calculation method 
(calculation was made on the basis of 
the majority-base call at each chro-
matogram position, and case sequenc-
es presented many mixed nucleotide 
positions) but also to immunotherapy. 
Treatment appeared to have decreased 
virus replication, probably by its ac-
tion mainly on species with greater ﬁ  t-
ness and higher replication rates (those 
that were more similar to the original 
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Sabin strain). As a consequence, treat-
ment might produce a bottleneck that 
unmasked more divergent species. 
Both the case and contact strains had 
intertypic Sabin 1/Sabin 2 recombina-
tion in nonstructural genes and also 
shared most of the nucleotide and 
amino acid substitutions. However, 
pathologic changes occurred only in 
the patient whose immunologic mech-
anisms were affected and whose viral 
load was consequently much higher. A 
recent report (1) suggests that VDPVs 
can emerge in any country that uses 
OPV with insufﬁ  cient vaccine cover-
age. In a polio-free IPV-user country, 
poliomyelitis can arise and spread to 
contacts who are not properly vacci-
nated. In the case we present here, the 
high level of vaccination coverage in 
Spain and the rapid control of close 
contacts achieved through the surveil-
lance and control programs prevented 
virus spread. In the global pre-eradica-
tion phase, countries are recommend-
ed to change vaccination from OPV to 
IPV. However, IPV-adopting countries 
commonly share borders with OPV-
adopting countries and residents may 
travel back and forth; thus, although 
the probability of VDPV circulation 
decreases, it does not reduce to zero. 
Therefore, active surveillance, rapid 
classiﬁ  cation of isolates, and molecu-
lar characterization of the virus are 
essential.
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Table. Laboratory methods used for study of vaccine-derived poliovirus case, Spain, 2005* 
Procedure Test Method† Sample
Concentration of sewage for detection of 
enterovirus in the environment 
Concentration with negative charge filters (Millipore, Billerica, MA, 
USA; 0.45 ȝm) of 20 L of local sewage 
E Sample
preparation 
RNA purification from samples (before 
molecular analysis) 
MagAttract Virus Mini-Biorobot (QIAGEN GmbH, Hilden, 
Germany) from 200 ȝL of stool sample dissolved in water 
S
Cellular culture (Biosafety Level 3) for 
growing PV 
LB20 (transgenic mouse), RD (human rhabdomyosarcoma), HEF 
(human fibroblast), A-549 (ATCC-CCL185) 
S, E 
Immunofluorescence of infected cells  Lim-Beyesh-Melnick A-H and RIVM A-G pools  I
Classic
virology 
techniques
EV neutralization assay  Antibodies (Chemicon, Temecula, CA, USA)  I
Molecular EV detection  RT-nested PCR 5c UTR (4) S, I, E 
Molecular EV quantification  MutaReal EV real-time PCR kit (Immunodiagnostik AG, 
Bensheim, Germany) 
S
Molecular  EV typing  RT-nested PCR in major VP1 region (5) S, I, E 
PV intratypic characterization  Specific vaccine PV RT-PCR (6) S, I, E 
PV genome sequencing fragment 1  1s: TAAAACAGCTCTGGGGTTGTA (2–22) 
1as: CACCACCCAAGAAGCGGCC (1023–1041) 
1ns: GCTCTGGGGTTGTACCCACTCC (9–30) 
1nas:TAACTCTGGGCAATTCAACGA(1001–1021) 
S, I 
PV genome sequencing fragment 2†  2s: CATGCTAAACTCCCCAAAC (945–963) 
2as: AGGTGCGCAACATGATGG (1882–1910) 
S, I 
PV genome sequencing fragment 3†  3s: CAGACAATTACCAGTCTCC (1814–1832) 
3as: ATTACTAAAAATGCATTGGTTCCC (2518–2541) 
S, I 
PV genome sequencing VP1 fragment†  VP1s: ACAACACACATTAGTCAAGAGGCTA (2449–2473) 
VP1as: GGATTTGGACACCAAAACAAAGC (3385–3407) 
S, I 
PV genome sequencing fragment 4†  4s:GTGCCCACGACCTCCA (3288–3303) 
4as: CTTGGGTGCGACATCTCA (4042–4059) 
S, I 
PV genome sequencing fragment 5†  5s: TAATCAAAATTATCTCATCACTTGTG (3962–3987) 
5as: CATGAGCGAGTACTCCAGA (4872–4889) 
S, I 
PV genome sequencing fragment 6†  6s: CTGGCCAGGAGATTCG (4834–4949) 
6as: AAATGATGGAGTTTTGATCGT(5725–5747) 
S, I 
PV genome sequencing fragment 7†  7s: AGGCAGGAACTAATCTTGAAA  (5630–5650) 
7as: CTAAGTATGTAGGCAACAAGAT (6164–6185) 
S, I 
PV genome sequencing fragment 8†  8s: CAAAAATGATCCCAGGCTCA (6117–6136) 
8as: AAACCTACAAGGGCATAGATT (6917–6937) 
S, I 
PV genome sequencing fragment 9†  9s: CAGGCACATCAATTTTTAACTC (6857–6878) 
9as: GGTAAATTTTTCTTTAATTCGGGG(7416–7439) 
S, I 
Molecular 
techniques
Additional PV sequencing primers  447as: CCGGCCCCTGAATGCGGC (447–464) 
4666s: CCAGACGGAGCAGACATG (4666–4683) 
S, I 
*E, local sewage; S, stools; I, isolates; EV, enterovirus; PV, poliovirus; UTR, untranslated region; VP1, virus capsid protein.
†Sense (s) and antisense (as) primers: 5co  3' sequence (position according to X00595). n, nested. All reverse transcription–PCR (RT-PCR) systems had 
the same conditions: 5 ȝL of clinical samples (case) or isolates (contacts) were added to the reaction mixture (final volume 50 ȝL): AMV/Tfl 1X reaction 
buffer, 2 mmol/L MgSO4, 200 ȝM each dNTP, 1 ȝM each primer, 5 U of AMV RT, and 5 U of Tfl DNA polymerase (Access RT-PCR System, Promega, 
Madison, WI, USA). First RT step of 45 min at 48°C, 2 min at 94°C, 45 cycles of denaturation (94°C, 2 min), annealing (53°C, 1 min), and elongation 
(68°C,1 min 30 s). LETTERS
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Widespread 
Oseltamivir 
Resistance in 
Inﬂ  uenza A 
Viruses (H1N1), 
South Africa 
To the Editor: Oseltamivir is the 
most widely used antiviral drug for 
inﬂ   uenza; it is a potent inhibitor of 
inﬂ   uenza virus neuraminidase (NA) 
protein (1). Until recently, oseltamivir 
resistance occurred in <1% of circu-
lating viruses globally. An increased 
number of inﬂ  uenza A viruses (H1N1) 
with resistance to oseltamivir was ﬁ  rst 
reported to the World Health Orga-
nization (WHO) by Norway in late 
January 2008. The viruses carried a 
speciﬁ  c histidine-to-tyrosine mutation 
at position 274 (H274Y; H275Y in N1 
numbering system) in the NA protein 
that confers high-level resistance to 
oseltamivir (2). Further surveillance 
by the European Surveillance Network 
for Vigilance against Viral Resistance 
and the WHO Global Inﬂ  uenza Sur-
veillance Network (GISN) showed 
that 16% of community isolates (0%–
67% by country) of inﬂ  uenza A virus-
es (H1N1) circulating in the 2007–08 
season in several other countries were 
also oseltamivir resistant (3). The pre-
dominant inﬂ  uenza subtype circulat-
ing in South Africa this winter season 
is H1N1. To determine whether oselta-
mivir-resistant viruses have spread to 
South Africa, we examined inﬂ  uenza 
A (H1N1) isolated during the 2008 
winter season for resistance to this an-
tiviral compound.
Specimens were obtained mainly 
from the National Institute of Com-
municable Diseases (NICD) active 
sentinel surveillance program in all 9 
provinces. Throat or nasopharyngeal 
swabs were taken from patients within 
48–72 hours of onset of symptoms and 
sent to NICD laboratories for virus 
isolation as described (4).
Of the H1N1 subtype viruses iso-
lated in May and June, 23 were sent 
to the WHO Collaborating Centers for 
Reference and Research on Inﬂ  uenza 
in London and Melbourne for resis-
tance testing (5,6). Forty-ﬁ  ve of the vi-
ruses, which included viruses isolated 
in July, were tested at NICD by using 
a modiﬁ  ed  ampliﬁ  cation  refractory 
mutation system PCR (ARMS-PCR) 
(7). This method can simultaneously 
detect wild-type or mutant virus with 
the 274 mutation in a single PCR. Par-
tial sequencing of the NA and hemag-
glutinin (HA) genes was performed to 
conﬁ  rm the NA H274Y resistance mu-
tation and to determine genetic drift 
in HA from the A/Brisbane/59/2007 
virus recommended for the Northern 
Hemisphere 2007–08 vaccine.
At the time of resistance testing, 
92 H1N1 subtype viruses had been 
isolated. The 23 virus isolates sent to 
the WHO Collaborating Centers were 
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